Management of HER2 alterations in non-small cell lung cancer - The past, present, and future
Jorn Nützinger1, Jii Bum Lee2, Jia Li Low1
1Department of Haematology-Oncology, National University Cancer Institute, Singapore.
Abstract:
HER2 mutations, which account for 2-4% of non-small cell lung cancer (NSCLC), are distinct molecular alterations identified via next generation sequencing (NGS). Previously, treatment outcomes in HER2-mutant metastatic NSCLC were dismal, showing limited clinical benefit with platinum-based chemotherapy with or without immunotherapy. In contrast to HER2-altered breast and gastric cancer, HER2-mutant NSCLC does not benefit from HER2 targeting agents such as trastuzumab or TDM1. HER2 mutations are also inherently different from HER2 overexpression and amplification. Currently, trastuzumab deruxtecan, a HER2 targeting antibody drug conjugate (ADC) is the first and only approved treatment option for patients with HER2-mutant metastatic NSCLC after failure with standard treatment. In this review, we summarized the biology of HER2 and detection of HER2 overexpression, amplification and mutations, as well as general landscape of landmark and ongoing clinical trials encompassing from chemotherapy to targeted agents, including tyrosine kinase inhibitors (TKIs), ADCs and investigational agents.
Insights
HER2 mutations in non-small cell lung cancer (NSCLC) previously had poor treatment outcomes. Trastuzumab deruxtecan, a novel antibody drug conjugate (ADC), is now the first approved therapy for HER2-mutant metastatic NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- HER2 mutations are found in 2-4% of non-small cell lung cancer (NSCLC) cases.
- Historically, HER2-mutant NSCLC showed limited response to chemotherapy and immunotherapy.
- Unlike breast and gastric cancers, HER2-mutant NSCLC does not respond to traditional HER2-targeting agents like trastuzumab or TDM1.
Purpose of the Study:
- To review the biology of HER2 alterations in NSCLC.
- To discuss methods for detecting HER2 overexpression, amplification, and mutations.
- To summarize the current treatment landscape, including clinical trials for targeted therapies.
Main Methods:
- Literature review of HER2 biology and detection methods.
- Analysis of clinical trial data for various treatment modalities.
- Synthesis of information on tyrosine kinase inhibitors (TKIs), antibody drug conjugates (ADCs), and other investigational agents.
Main Results:
- Trastuzumab deruxtecan (ADC) is the first and only approved treatment for HER2-mutant metastatic NSCLC post-standard therapy failure.
- HER2 mutations represent a distinct molecular subtype in NSCLC, differing from HER2 overexpression/amplification.
- Ongoing clinical trials are exploring various targeted agents, including TKIs and ADCs.
Conclusions:
- HER2-mutant NSCLC requires specific therapeutic strategies distinct from other HER2-driven cancers.
- Trastuzumab deruxtecan offers a new, approved treatment avenue for this patient population.
- Further research and clinical trials are crucial for advancing treatment options for HER2-mutant NSCLC.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...